New drugs bring hope to ALS patients
Recently, attention has again been focused on ALS. The fatal neurological disease has long been one of the biggest medical mysteries. Today, the knowledge...
A breakthrough in Alzheimer’s drug development?
As the societal burden of Alzheimer’s disease continues to grow, drug development in the field has struggled to keep up the pace. A huge...
Patient perspective in focus in Abliva’s phase II/III study
Biotech company Abliva is now preparing for the perhaps biggest step in the company's history to date – a pivotal phase II/III study with...
BioStock Investor Meeting: Interview with Lipum
Biopharmaceutical company Lipum is approaching clinical studies with the candidate SOL-116, which targets chronic inflammatory diseases such as rheumatoid arthritis. CEO Einar Pontén presented the...
Top 5 life science stocks – first half of 2022
For known reasons, it has been a rough first half of the year for the stock market. Several of the world's leading indices lost...
Last clinic visit completed in Promore Pharma’s ensereptide study
The most important activity for Promore Pharma in 2022 has been the phase IIa study with drug candidate ensereptide. The company announced earlier this...
Cancer vaccines – a new frontier in immuno-oncology
Ever since their discovery more than 200 years ago, vaccines have helped revolutionise healthcare, especially when it comes to combatting deadly infectious diseases. As...
The Ukraine crisis – an ethical dilemma for the life science...
Russia's inhumane invasion of Ukraine is putting pressure on the life science sector. The major pharmaceutical companies are now pausing clinical studies and other...
Iconovo’s new collaboration aims to optimise current inhalation products
British CrystecPharma begins a collaboration with the Swedish inhaler developer Iconovo with the aim of formulating new innovative compounds for use in dry powder...
Scandion Oncology ready for phase II with SCO-101
Scandion Oncology’s candidate SCO-101 is being developed to fight resistance to cancer drugs and is ready to enter phase II clinical trials. Metastatic colorectal...
